The second-generation ABL TKI dasatinib could yield remarkable responses in the treatment of imatinib-resistant Ph+ B-ALL patients by co-targeting BCR-ABL and SRC family kinases [5, 6]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.